Horwitz, S ;
O'Connor, O A ;
Pro, B...
Horwitz , S , O'Connor , O A , Pro , B , Trümper , L , Iyer , S , Advani , R , Bartlett , N L , Christensen , J H , Morschhauser , F , Domingo-Domenech , E , Rossi , G , Kim , W S , Feldman , T , Menne , T , Belada , D , Illés , Á , Tobinai , K , Tsukasaki , K , Yeh , S-P , Shustov , A , Hüttmann , A , Savage , K J , Yuen , S , Zinzani , P L , Miao , H , Bunn , V , Fenton , K , Fanale , M , Puhlmann , M & Illidge , T 2021 , ' The ECHELON-2 Trial : 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma ' , Annals of oncology : official journal of the European Society for Medical Oncology , vol. 33 , no. 3 , pp. 288-298 . https://doi.org/10.1016/j.annonc.2021.12.002.
,
2021
